| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 37.5 | 36.2 |
| Profit before tax | -137.3 | -118.7 |
| Net income | -103.6 | -89.0 |
| EPS (diluted, $ a share) | $-2.21 | $-2.46 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +3.7% |
|---|---|
| Operating margin | -385.3% |
10-Q filed with the SEC, NASDAQ: GRAL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
GRAIL, Inc.: key numbers
- Share price
- $105.60Close, Nov 16
- Market cap
- $4.75B
- Shares outstanding
- 44.96MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from GRAIL, Inc.
All →GRAIL CFO Aaron Freidin Sells $323K of Stock
Aaron Freidin, CFO, sold 3,000 shares of GRAIL, Inc. at $104.97 to $112.53 a share (average $107.62) in 6 transactions, worth $323K in total on Nov 16, 2026. Shares held after the trade: 222,364 (-0.0%).
- Value
- $323K
- Shares
- 3,000
- Average price
- $107.62
- Role
- CFO
- Holding change
- -0.0%
- Trade date
- Nov 16, 2026
GRAIL Financial Results
GRAIL reported third quarter 2026 financial results, highlighted by a 14% year-over-year increase in Galleri test revenue to $37.3 million and a favorable FDA Advisory Committee vote for the Galleri multi-cancer early detection test. The company reported a net loss of $103.6 million for the quarter and maintains a cash position of $788.7 million as it anticipates an FDA approval decision by early Q1 2027.
“GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee. This achievement strengthens the foundation for Galleri as we continue on our path towards potential regulatory approval, broader access and reimbursement. We are seeing continued commercial momentum as a number of positive advancements, consistent market education, and promotional pricing initiatives gain traction.”
Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL
GRAIL CEO Joshua J. Ofman Sells $2.74M of Stock
Joshua J. Ofman, CEO, sold 20,000 shares of GRAIL, Inc. at $133.12 to $138.79 a share (average $136.85) in 6 transactions, worth $2.74M in total on Oct 15, 2026. Shares held after the trade: 342,271 (-0.6%).
- Value
- $2.74M
- Shares
- 20,000
- Average price
- $136.85
- Role
- CEO
- Holding change
- -0.6%
- Trade date
- Oct 15, 2026
GRAIL CFO Aaron Freidin Sells $3.46M of Stock
Aaron Freidin, CFO, sold 23,619 shares of GRAIL, Inc. at $146.39 a share, worth $3.46M in total on Oct 5, 2026. Shares held after the trade: 225,364 (-9.5%).
- Value
- $3.46M
- Shares
- 23,619
- Price
- $146.39
- Role
- CFO
- Holding change
- -9.5%
- Trade date
- Oct 5, 2026
GRAIL Chief Growth Officer Andrew John Partridge Sells $1.15M of Stock
Andrew John Partridge, Chief Growth Officer, sold 7,873 shares of GRAIL, Inc. at $146.39 a share, worth $1.15M in total on Oct 5, 2026. Shares held after the trade: 155,865 (-4.8%).
- Value
- $1.15M
- Shares
- 7,873
- Price
- $146.39
- Role
- Chief Growth Officer
- Holding change
- -4.8%
- Trade date
- Oct 5, 2026